Department of Pharmacy, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, 3000, Australia.
The Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, 3050, Australia.
Res Social Adm Pharm. 2021 Mar;17(3):613-618. doi: 10.1016/j.sapharm.2020.05.023. Epub 2020 May 28.
Patients diagnosed with cancer are often treated with high dose glucocorticosteroids, increasing their risk of developing hyperglycaemia or steroid-induced diabetes, which can be reduced by regular monitoring of blood glucose levels. Community pharmacies can provide easily accessible monitoring services to patients, but may not be convenient or acceptable for people with a cancer diagnosis.
To explore patients' motivations, perceptions of benefits and barriers influencing their decisions to participate in a novel community pharmacy-based hyperglycaemia screening and monitoring program.
Patients initiated on high-dose-glucocorticosteroids at a quaternary cancer centre, who were meeting risk factor-based inclusion criteria and offered participation in a community-based blood glucose monitoring program, were purposively recruited to semi-structured interviews. Interview transcripts were analysed using content analysis and the Framework Method.
Twenty-four patients participated in the interviews, of whom eighteen enrolled into the monitoring program and six declined participation. Interview analysis identified themes of motivators and barriers which were interpreted within the Health Belief Model. Patients individually balanced perceptions of risk and susceptibility to hyperglycaemia with the illness and treatment burden of a cancer diagnosis and the ability to access the program. Health concerns, accessibility of the community pharmacy, trust in healthcare professionals and altruism of patients (giving back) were identified as enablers to enrol. Barriers were inaccessibility of the community pharmacy, extra burden to deal with monitoring appointments, and initial misunderstandings about the screening and monitoring program.
Ascertaining individual tipping points based on motivators or enablers and barriers with subsequent tailoring of supportive care programs will be more likely to meet patients' individual needs and may increase the likelihood of delivering appropriate care via community pharmacies.
患有癌症的患者通常接受大剂量糖皮质激素治疗,这会增加其发生高血糖或类固醇诱导型糖尿病的风险,通过定期监测血糖水平可以降低这种风险。社区药店可以为患者提供方便的监测服务,但对于癌症患者来说,可能不太方便或难以接受。
探讨影响患者参与新型社区药店高血糖筛查和监测计划的决定的动机、对益处的认知和障碍因素。
在一家四级癌症中心接受大剂量糖皮质激素治疗、符合基于风险因素的纳入标准并被邀请参与社区血糖监测计划的患者被有目的地招募参加半结构式访谈。使用内容分析和框架方法对访谈记录进行分析。
24 名患者参加了访谈,其中 18 名参加了监测计划,6 名拒绝参加。访谈分析确定了动机和障碍主题,并在健康信念模型中进行了解释。患者个人权衡了对高血糖的风险和易感性与癌症诊断和治疗负担以及获得该计划的能力之间的关系。健康问题、社区药店的可及性、对医疗保健专业人员的信任以及患者的利他主义(回馈社会)被认为是参与的促成因素。障碍包括社区药店难以到达、监测预约带来额外负担以及对筛查和监测计划的初步误解。
根据动机或促成因素以及障碍来确定个人的临界点,并随后对支持性护理计划进行定制,更有可能满足患者的个人需求,并可能增加通过社区药店提供适当护理的可能性。